Logo image of PSTX

POSEIDA THERAPEUTICS INC (PSTX) Stock Fundamental Analysis

NASDAQ:PSTX - Nasdaq - US73730P1084 - Common Stock - Currency: USD

9.5  -0.06 (-0.63%)

After market: 9.54 +0.04 (+0.42%)

Fundamental Rating

2

Overall PSTX gets a fundamental rating of 2 out of 10. We evaluated PSTX against 559 industry peers in the Biotechnology industry. PSTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PSTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PSTX has reported negative net income.
PSTX had a negative operating cash flow in the past year.
In the past 5 years PSTX always reported negative net income.
In the past 5 years PSTX always reported negative operating cash flow.
PSTX Yearly Net Income VS EBIT VS OCF VS FCFPSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

PSTX has a better Return On Assets (-20.70%) than 77.25% of its industry peers.
PSTX's Return On Equity of -69.67% is in line compared to the rest of the industry. PSTX outperforms 56.08% of its industry peers.
Industry RankSector Rank
ROA -20.7%
ROE -69.67%
ROIC N/A
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
PSTX Yearly ROA, ROE, ROICPSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800 1K

1.3 Margins

PSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTX Yearly Profit, Operating, Gross MarginsPSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

PSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PSTX has more shares outstanding
Compared to 1 year ago, PSTX has a worse debt to assets ratio.
PSTX Yearly Shares OutstandingPSTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
PSTX Yearly Total Debt VS Total AssetsPSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

PSTX has an Altman-Z score of 0.21. This is a bad value and indicates that PSTX is not financially healthy and even has some risk of bankruptcy.
PSTX has a Altman-Z score of 0.21. This is in the better half of the industry: PSTX outperforms 65.26% of its industry peers.
A Debt/Equity ratio of 0.68 indicates that PSTX is somewhat dependend on debt financing.
PSTX has a worse Debt to Equity ratio (0.68) than 77.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z 0.21
ROIC/WACCN/A
WACC10.98%
PSTX Yearly LT Debt VS Equity VS FCFPSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.20 indicates that PSTX has no problem at all paying its short term obligations.
PSTX's Current ratio of 3.20 is on the low side compared to the rest of the industry. PSTX is outperformed by 62.43% of its industry peers.
PSTX has a Quick Ratio of 3.20. This indicates that PSTX is financially healthy and has no problem in meeting its short term obligations.
PSTX's Quick ratio of 3.20 is on the low side compared to the rest of the industry. PSTX is outperformed by 60.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.2
PSTX Yearly Current Assets VS Current LiabilitesPSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

PSTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.28%, which is quite impressive.
The Revenue has grown by 202.93% in the past year. This is a very strong growth!
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%

3.2 Future

PSTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.75% yearly.
PSTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.27% yearly.
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%

3.3 Evolution

PSTX Yearly Revenue VS EstimatesPSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
PSTX Yearly EPS VS EstimatesPSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PSTX. In the last year negative earnings were reported.
Also next year PSTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTX Price Earnings VS Forward Price EarningsPSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTX Per share dataPSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POSEIDA THERAPEUTICS INC

NASDAQ:PSTX (1/7/2025, 8:07:14 PM)

After market: 9.54 +0.04 (+0.42%)

9.5

-0.06 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners55.52%
Inst Owner Change-95.42%
Ins Owners0.89%
Ins Owner Change-85.71%
Market Cap925.97M
Analysts50
Price Target9.18 (-3.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.77%
Min EPS beat(2)23.01%
Max EPS beat(2)150.52%
EPS beat(4)4
Avg EPS beat(4)61.65%
Min EPS beat(4)23.01%
Max EPS beat(4)150.52%
EPS beat(8)6
Avg EPS beat(8)25.24%
EPS beat(12)9
Avg EPS beat(12)43.35%
EPS beat(16)12
Avg EPS beat(16)33.55%
Revenue beat(2)2
Avg Revenue beat(2)198.71%
Min Revenue beat(2)64.99%
Max Revenue beat(2)332.43%
Revenue beat(4)4
Avg Revenue beat(4)200.6%
Min Revenue beat(4)64.99%
Max Revenue beat(4)332.43%
Revenue beat(8)6
Avg Revenue beat(8)122.25%
Revenue beat(12)10
Avg Revenue beat(12)1069.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.26%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.28%
EPS NY rev (1m)0%
EPS NY rev (3m)32.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)69.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.14
P/FCF N/A
P/OCF N/A
P/B 10.62
P/tB 11.34
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.55
BVpS0.89
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.7%
ROE -69.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.31%
Cap/Sales 1.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 3.2
Altman-Z 0.21
F-Score4
WACC10.98%
ROIC/WACCN/A
Cap/Depr(3y)62.75%
Cap/Depr(5y)254.95%
Cap/Sales(3y)5.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%
EBIT growth 1Y54.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.41%
OCF growth 3YN/A
OCF growth 5YN/A